Melatonin Improves Sleep Quality of Patients With Chronic Schizophrenia

Shamir, Eyal; Laudon, Moshe; Barak, Yoram; Anis, Yossi; Rotenberg, Vadim S.; Elizur, Avner; Zisapel, Nava

doi:10.4088/jcp.v61n0509

Cited by 122 publications

(75 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Within the central nervous system (CNS), it is involved in several important catabolic pathways including those of serotonin and kynurenine [1,2]. The overview of tryptophan catabolism with relationships with CNS diseases [3][4][5][6][7][8][9][10][11] is illustrated in Figure 1.…”

Section: Introductionmentioning

confidence: 99%

Study of the Activity and Possible Mechanism of Action of a Reversible Inhibitor of Recombinant Human KAT-2: A Promising Lead in Neurodegenerative and Cognitive Disorders

et al. 2016

View full text Add to dashboard Cite

Abnormal levels of kynurenic acid (KYNA) in the human brain are believed to be connected to several central nervous system (CNS) diseases, therefore compounds which affect the production of this crucial metabolite are of interest in CNS drug development. The majority of KYNA production is accounted for by kynurenine aminotransferase-2 (KAT-2) in the mammalian brain; hence this enzyme is one of the most interesting targets with which to modulate KYNA levels. Recently developed human KAT-2 inhibitors with high potencies are known to irreversibly bind to the enzyme cofactor, pyridoxal-5 1 -phosphate (PLP), which may lead to severe side effects due to the abundance of PLP-dependent enzymes. In this study, we report a reversible and competitive inhibitor of KAT-2. Its inhibitory activities were examined using HPLC and surface plasmon resonance (SPR) and compare favorably with other recently reported KAT-2 inhibitors. Our inhibitor, NS-1502, demonstrates suitable inhibitory activity, almost 10 times more potent than the known reversible KAT-2, (S)-ESBA.

show abstract

Section: Introductionmentioning

confidence: 99%

Study of the Activity and Possible Mechanism of Action of a Reversible Inhibitor of Recombinant Human KAT-2: A Promising Lead in Neurodegenerative and Cognitive Disorders

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Esto acentúa la importancia de sospechar y tratar dichas condiciones en estos pacientes. Estudios preliminares muestran a la melatonina, en la EQZ, como un importante foco terapéutico, pero se requiere mayor investigación para garantizar su utilidad 21 .…”

Section: Disrupción De Ritmo Circadianounclassified

Esquizofrenia y su asociación con enfermedades médicas crónicas

et al. 2017

View full text Add to dashboard Cite

The life expectancy of patients with schizophrenia (SCH) is 11 to 20 years less than the general population. There is an association between SCH and various diseases and chronic conditions, highlighting the cardio-metabolic diseases. This association has been attributed to the use of antipsychoticsSe caracteriza por síntomas positivos (alucinaciones, delirio, síntomas catatónicos y discurso desorganizado), negativos (aplanamiento afectivo y anhedonia) y disfunciones cognitivas (alteración de atención, memoria y funciones ejecutivas) 1 . Además, hay perturbaciones fisiológicas severas que aumentan la gravedad de la EQZ, de hecho, se evidencian alteraciones endocrinológicas, del sueño, cardiovasculares y metabólicas con alteración del peso, regulación de glicemia, metabolismo lipídico y presión arterial, cuyos mecanismos no se conocen del todo 2 .La expectativa de vida de los pacientes con EQZ es entre 11 y 20 años menor que la población general y la mortalidad cardiovascular ha aumentado en este grupo de pacientes, en contraste a la población general 3 .El tratamiento antipsicótico siempre se ha asociado a estas alteraciones cardiometabólicas, sin embargo, la evidencia muestra que pacientes que nunca han recibido tratamiento también presentan estas patologías concomitantes 4 , además que muchas de ellas se encuentran desde el primer episodio psicótico, por ende, se postula que la EQZ per se estaría relacionada con esta alteración 5,6 .Este trabajo pretende actualizar los conocimientos con respecto a comorbilidades médicas crónicas asociadas a la EQZ y ayudar así a optimizar el manejo clínico de estos pacientes.

show abstract

“…(16,(24)(25)(26)(27)(28) Anxiolytic and antidepressant effects of melatonin are associated with its biorythmological and normalizing effects on sleep and on the level of endogenous peptides. Melatonin is not only a unique synchronizer of endogenous biological rhythms, but also to a certain extent is a tranquilizer.…”

Section: Resultsmentioning

confidence: 99%

Melatonin in Treatment of Sleep Disorders in Elderly Patients with Chronic Obstructive Pulmonary Disease

Цветикова¹,

Гончаренко²,

Budnevsky³

et al. 2017

IJBM

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease (COPD) may frequently be complicated by sleep disorders, which worse quality of life and lead to other adverse consequences. The objective of the study was to analyze clinical course of the disease and quality of life in elderly patients with both COPD and sleep disorders. Methods and Results:The study included 50 patients with moderate and severe COPD in age from 60 to 75 years (mean age, 66.12±0.76 years). Patients were divided into 2 groups randomly. For patients in Group 1, 3 mg of melatonin was prescribed orally 30-40 minutes before bedtime for 14 days on the background of standard COPD therapy. Patients of Group 2 received only standard COPD therapy. After 12 months of follow-up, the number of exacerbations and hospitalizations for COPD significantly decreased in Group 1: from 3.74±0.19 to 1.91±0.20 times a year (P=0.0000) and from 2.08±0.18 to 1.35±0.18 (P=0.0046). In Group 2, the dynamics of these parameters was not statistically significant. In addition, along with the improvement of sleep quality in COPD patients during treatment with melatonin, both state and trait anxiety scores and depression level improved. In Group 1, SF-36 scores (PF, RP, BP, and GH) have also significantly improved.Conclusion: Correction of sleep disorders by melatonin in elderly patients with COPD improved the effectiveness of COPD treatment, and reduced the frequency and duration of exacerbations and the number of outpatient visits and hospitalizations.

show abstract

Melatonin Improves Sleep Quality of Patients With Chronic Schizophrenia

Cited by 122 publications

References 0 publications

Study of the Activity and Possible Mechanism of Action of a Reversible Inhibitor of Recombinant Human KAT-2: A Promising Lead in Neurodegenerative and Cognitive Disorders

Study of the Activity and Possible Mechanism of Action of a Reversible Inhibitor of Recombinant Human KAT-2: A Promising Lead in Neurodegenerative and Cognitive Disorders

Esquizofrenia y su asociación con enfermedades médicas crónicas

Melatonin in Treatment of Sleep Disorders in Elderly Patients with Chronic Obstructive Pulmonary Disease

Contact Info

Product

Resources

About